Brandon Vara

Brandon Vara

Auto-generated profile, based on publicly available information

Brandon Vara

Merck & Co., Inc.

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2017 in Chemical Science
Verified
Journal Article
Open access
PDF file
BVBrandon A. Vara
Brandon A. Vara
XLXingpin Li
Xingpin Li
SBSimon Berritt
Simon Berritt
CWChristopher R. Walters
Christopher R. Walters
EPE. James Petersson
E. James Petersson
GMGary A. Molander
Gary A. Molander
Site-specific functionalization of unprotected native peptides and biomolecules remains a useful transformation in synthetic design and chemical biology, yet until recently, advancements in transition metal-catalyzed methods, which have prevailed in organic synthesis, have been relatively ineffective when applied to large and structurally complex biomolecules. Here, the mechanistically distinct, Ni/photoredox-catalyzed arylation of unprotected, native thiols (e.g., cysteine residues) is reported – a process initiated through a visible light-promoted, hydrogen atom transfer (HAT) event under ambient conditions. Sub-stoichiometric loadings of the dual-catalyst system (≤5 mol%) are employed, granting excellent site-specificity, broad substrate scope, and low chemical waste. Reaction scalability (from μg to grams) has been achieved through modest reagent adjustments, and high throughput experimentation (HTE) demonstrates the ease of reaction setup, enabling prompt screening of aryl halide coupling partners and conditions. Scores of thiol substrates and aryl entities were examined and effectively conjugated, suggesting further diverse, practical applications.

19 March 2021 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
BVBrandon A. Vara
Brandon A. Vara
SLSamuel M. Levi
Samuel M. Levi
AAAbdelghani Achab
Abdelghani Achab
DCDavid A. Candito
David A. Candito
XFXavier Fradera
Xavier Fradera
APAlexander Pasternak
Alexander Pasternak

6 March 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
CMCasey J. Moure
Casey J. Moure
BVBrandon Vara
Brandon Vara
MCMangeng M. Cheng
Mangeng M. Cheng
CSChristopher Sondey
Christopher Sondey
EMEric Muise
Eric Muise
EBEvan R Barry
Evan R Barry
Many tumor types harbor alterations in the Hippo pathway, including mesothelioma, where a high percentage of cases are considered YAP1/TEAD dependent. Identification of autopalmitoylation sites in the hydrophobic palmitate pocket of TEADs, which may be necessary for YAP1 protein interactions, has enabled modern drug discovery platforms to generate compounds that allosterically inhibit YAP1/TEAD complex formation and transcriptional activity. We report the discovery and characterization of a novel YAP1/TEAD inhibitor MRK-A from an aryl ether chemical series demonstrating potent and specific inhibition of YAP1/TEAD activity. In vivo, MRK-A showed a favorable tolerability profile in mice and demonstrated pharmacokinetics suitable for twice daily oral dosing in preclinical efficacy studies. Importantly, monotherapeutic targeting of YAP1/TEAD in preclinical models generated regressions in a mesothelioma CDX model; however, rapid resistance to therapy was observed. RNA-sequencing of resistant tumors revealed mRNA expression changes correlated with the resistance state and a marked increase of hepatocyte growth factor (HGF) expression. In vitro, exogenous HGF was able to fully rescue cytostasis induced by MRK-A in mesothelioma cell lines. In addition, co-administration of small molecule inhibitors of the MET receptor tyrosine kinase suppressed the resistance generating effect of HGF on MRK-A induced growth inhibition. In this work, we report the structure and characterization of MRK-A, demonstrating potent and specific inhibition of YAP1/TAZ-TEAD–mediated transcriptional responses, with potential implications for treating malignancies driven by altered Hippo signaling, including factors resulting in acquired drug resistance.

12 February 2026 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
BVBrandon A. Vara
Brandon A. Vara
JLJongwon Lim
Jongwon Lim
CMCasey J. Moure
Casey J. Moure
SSSebastian E. Schneider
Sebastian E. Schneider
CYCharles S. Yeung
Charles S. Yeung
VSVladimir Simov
Vladimir Simov

5 May 2026 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YZYonglian Zhang
Yonglian Zhang
EHElisabeth Hennessy
Elisabeth Hennessy
MLMatthew A. Larsen
Matthew A. Larsen
JHJingsong Hao
Jingsong Hao
JPJianping Pan
Jianping Pan
DDDuane E. DeMong
Duane E. DeMong

16 September 2024
Verified
Other
Open access
CMCasey J. Moure
Casey J. Moure
BVBrandon Vara
Brandon Vara
MCMangeng M. Cheng
Mangeng M. Cheng
CSChristopher Sondey
Christopher Sondey
EMEric Muise
Eric Muise
EBEvan R Barry
Evan R Barry
Supplementary table 2 from Activation of Hepatocyte Growth Factor/MET Signaling as a Mechanism of Acquired Resistance to a Novel YAP1/TEAD Small Molecule Inhibitor